Short answer
ZEVRA THERAPEUTICS, INC. (ZVRA) filed an 8-K current report with the SEC on November 3, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q3 2026 financial results and corporate updates announced for quarter ended September 30, 2026.
ZEVRA THERAPEUTICS, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q3 2026 financial results and corporate updates announced for quarter ended September 30, 2026
- Investor conference call and audio webcast scheduled for November 3, 2026, at 4:30 p.m. ET
- Detailed financial figures and management commentary contained in Exhibit 99.1 press release
Item EX-99.1 · Exhibit EX-99.1
- Q3 revenue $37.8M, up $11.7M from Q3 2025, with MIPLYFFA contributing $34.0M
- Net income $19.2M, or $0.26 diluted EPS, versus a $0.5M loss, aided by $5.1M warrant and CVR liability gains
- Cash, equivalents and investments $270.9M, supporting commercialization, pipeline development and expanded-access activities
- MIPLYFFA enrollment reached 197 U.S. prescriptions and 134 global EAP patients, indicating continued commercial expansion
- Celiprolol Phase 3 enrollment reached 72 patients with four confirmed events, while potential MIPLYFFA infant-label expansion targets Q1 2027 filing
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other ZEVRA THERAPEUTICS, INC. 8-K filings
Get the next ZVRA 8-K as it lands
Follow ZVRA for push alerts, or ask the research agent what this filing means.